Vaccination; Infection
21
4
4
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.8%
1 terminated out of 21 trials
90.9%
+4.4% vs benchmark
24%
5 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (21)
Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV
Maternal Determinants of Infant Immunity to Pertussis
Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure
Monitoring COVID-19 Vaccination Response in Fragile Populations
Maternal Determinants of Immunity to Influenza
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
COVID-19 Serology in People Living with HIV in Hong Kong
Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAX
Triage Survey for Infectious Disease Eligibility
Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly
Effect of Health Education on Promoting Influenza Vaccination Health Literacy
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine
The Influence of Trained Immunity in COVID-19 Vaccinated Individuals
Post Covid-19 Vaccination Development or Flare of ARD
Anti-Schistosomiasis Sm14-vaccine in Senegal
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years Old
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women
Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine
Immune Response to Vaccination Against Covid-19, a Follow up Study
Risk of COVID-19 Infection After Vaccination